Iceland· IS-EU/1/08/497/007-008
Nplate
A romiplostim product containing romiplostimum inn, registered in Iceland by Amgen Europe B.V.*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Romiplostim is registered in 14 of 19 countries.
Countries holding a registration under ATC B02BX04 (romiplostim), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Romiplostim · ATC B02BX04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of romiplostim costs, country by country.
Normalised to the WHO defined daily dose (30 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Romiplostim · price per daily dose (30 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$72.77
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Romiplostimum INN
- Manufacturer
- Amgen Europe B.V.*
- Country
- Iceland (IS)
- ATC code
- B02BX04
- ATC class
- Romiplostim
- Defined daily dose
- 30 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for romiplostim.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Romiplostim · interactions on record
2 records
- 2 severe
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Romiplostim in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNPLATEAmgen Europe B.V., Breda
- United StatesNplateAmgen, Inc
- BelgiumNplate 125 µgAmgen Europe
- FinlandNplateAmgen Europe B.V.
- PolandNplateAmgen Europe B.V.
- SwedenNplate 125 mikrogram Pulver till injektionsvätska, lösningAmgen Europe B.V.
- SpainNPLATE 250 microgramos POLVO PARA SOLUCION INYECTABLEAmgen Europe B.V.
- IrelandNplate 250 microgramsAmgen Europe B.V.,
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Norway · Nplate
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4b46599b-6635-4a36-b717-a9ceb180a49a GET /v1/drugs/4b46599b-6635-4a36-b717-a9ceb180a49a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyfsstofn og leysir, lausn",
"source": "lyfjastofnun",
"atc_raw": "B02BX04",
"marketed": false,
"strength": "500 míkróg",
"ma_number": "EU/1/08/497/007-008",
"substance": "Romiplostimum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "40200"
}See everything about romiplostim.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.